Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07503808 · ClinicalTrials.gov registry record · Phase 1

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

A Phase 1 study, sponsored by IDEAYA Biosciences.

Recruiting
Registry status
Phase 1
Development phase
150
Enrollment target

NCT07503808: Recruiting Phase 1 study, sponsored by IDEAYA Biosciences.

NCT07503808 is a Phase 1 study that is actively recruiting participants, run by IDEAYA Biosciences. The registered enrollment target is 150 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (150% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07503808, a Phase 1 study, is actively recruiting participants, sponsored by IDEAYA Biosciences.

RECRUITING
Registry status
Phase 1
Development phase
150 participants
Enrollment target

Study Summary

This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.

Primary Outcome

Incidence of dose limiting toxicities; incidence and severity of AEs and SAEs graded based on CTCAE V6.0

Interventions

  • DRUG IDE034

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2026-02-24
Est. Completion 2027-07-30
Phase Phase 1
IDEAYA Biosciences

10 total trials

What NCT07503808 shows while recruiting

NCT07503808 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (150% higher).

The record links to 0 conditions, and to 1 intervention - of which IDE034 is the first listed.

NCT07503808 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07503808 about?

NCT07503808 is a clinical study titled "A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types". This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.

What is the current status of trial NCT07503808?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2026-02-24. Estimated completion is 2027-07-30.

What interventions are being tested in trial NCT07503808?

The interventions under investigation include: IDE034 (DRUG).

Who is sponsoring clinical trial NCT07503808?

This trial is sponsored by IDEAYA Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07503808's enrollment target sits among peer trials

150 363rd of 2000 higher than 1,620 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07503808, the US trial registry maintained by the National Library of Medicine. NCT07503808 (mid enrollment · none site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.